SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Razoxane

Cat. No.: HY-119425

CAS No.: 21416-67-1

Molecular Formula: $C_{11}H_{16}N_4O_4$

Molecular Weight: 268.27

Target: Topoisomerase

Pathway: Cell Cycle/DNA Damage

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (372.76 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.7276 mL	18.6379 mL	37.2759 mL
	5 mM	0.7455 mL	3.7276 mL	7.4552 mL
	10 mM	0.3728 mL	1.8638 mL	3.7276 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].

IC_{50} & Target

Topoisomerase II

In Vitro

Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley rats[2]
Dosage:	30 mg/kg or 10 mg/kg per day
Administration:	Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation
Result:	Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.

REFERENCES

[1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704.

[2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA